Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Breegi Scientific, Lifesignals, Mindpeak, Tasso.
The top 100 public biopharmaceutical companies with market caps greater than $1 billion, and excluding big pharma companies, spent a total of almost $12 billion on R&D in the first quarter of 2021, compared to $9.4 billion invested last year.
Although more than a third of U.S. citizens are fully vaccinated from COVID-19 and society moves closer to normalcy in many parts of the world, the SARS-CoV-2 virus continues to dramatically impact biopharma dealmaking with nonprofit entities, as well as grant awards.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acceleron, Apeiron, Astrazeneca, Biomarin, CNS, Cytokinetics, Galapagos, Idera, Immunocore, Pfizer, Silence, Veru.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Avisa Diagnostics, Binx Health, Bio-Teche, Discovery Life Sciences, Fogchain, Medline Industries, Seegene, Sherlock Biosciences, Targos Molecular Pathology, Teleflex, Water Street Healthcare Partners.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Boston Scientific, Diadem, Heartflow, Novocure, Stratus Medical, Ultromics.
In a rare move, the FDA disclosed summary trial information May 17 about Cytodyn Inc.’s Vyrologix (leronlimab), noting that currently available data don’t support the clinical benefit of the drug as a COVID-19 treatment.
DUBLIN – Bergenbio ASA joins an expanding list of companies whose candidate drug has failed to attain the primary endpoint of a clinical trial in COVID-19.
RSS
